Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 181-190 of 236 for multiple myeloma

Edit search filters
  1. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies

    Rochester, MN

  2. Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

    Scottsdale/Phoenix, AZ

  4. Study Of SIM0500 Alone In Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Study to Evaluate CCS1477 in Haematological Malignancies

    Scottsdale/Phoenix, AZ

  6. Selinexor Treatment of Refractory Myeloma

    Rochester, MN, Scottsdale/Phoenix, AZ

  7. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Study Of ABBV-383 Assessing Adverse Events And Clinical Activity With Subcutaneous (SC) Injection In Adult Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  10. A Study Of Belantamab Mafodotin Administered In Combination With Lenalidomide And Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible For Autologous Stem Cell Transplantation (TI-NDMM)

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer